SCHEMBL10108810

SCHEMBL10108810

COc1ccc2c(c1)[C@@H]1CCCC[C@@H]1CC2=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP19A1 P11511 8/20 0.43
MAOB P27338 6/20 0.43
CYP3A4 P08684 1/20 0.43
ACHE P22303 1/20 0.42
NOS3 P29474 1/20 0.41
NOS1 P29475 1/20 0.41
NOS2 P35228 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
METAP1 P53582 1/20 0.40
MAP2K3 P46734 1/20 0.40
KMT2A Q03164 1/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL318058 1.00 LMNA (0.47) LMNAGAAKDM4EALDH1A1CYP19A1
SCHEMBL10108843 0.97 LMNA (0.47) LMNAGAAKDM4EALDH1A1CYP19A1
SCHEMBL318173 0.97 LMNA (0.47) LMNAGAAKDM4EALDH1A1CYP19A1
SCHEMBL318168 0.89 ACHE (0.46) GAAKDM4EALDH1A1CYP19A1MAOB
SCHEMBL10109000 0.89 ACHE (0.46) GAAKDM4EALDH1A1CYP19A1MAOB
SCHEMBL318226 0.80 LMNA (0.43) LMNAGAAKDM4EALDH1A1CYP19A1
SCHEMBL10109092 0.80 LMNA (0.43) LMNAGAAKDM4EALDH1A1CYP19A1
SCHEMBL6556380 0.80 SIGMAR1 (0.50) LMNAGAAKDM4EALDH1A1CYP19A1
SCHEMBL10109039 0.80 LMNA (0.43) LMNAGAAKDM4EALDH1A1CYP19A1
SCHEMBL318041 0.80 LMNA (0.43) LMNAGAAKDM4EALDH1A1CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093302-B2 Substituted tetralins as selective estrogen receptor-β agonists ELI LILLY AND COMPANY (US) 2012-01-10 US disclosed
US-8093302-B2 Substituted tetralins as selective estrogen receptor-β agonists ELI LILLY AND COMPANY (US) 2012-01-10 US disclosed
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2010-09-30 US disclosed
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ESR2, ERLIN1, ESRRG LMNA 2755/4885GAA 2018/4885KDM4E 2531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.